---
layout: default
title: Rasagiline Tartrate
parent: 僅模型預測 (L5)
nav_order: 59
evidence_level: L5
indication_count: 0
---

# Rasagiline Tartrate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# RASAGILINE TARTRATE: Evaluation Incomplete — Awaiting Data

## One-Sentence Summary

RASAGILINE TARTRATE is a drug with no marketing authorization in Taiwan and no approved indications recorded in the regulatory database.
The TxGNN prediction pipeline did not return any new indication candidates for this compound in the current Evidence Pack, and critical data — including mechanism of action and safety profile — remain unresolved data gaps.
A complete drug repurposing evaluation cannot be conducted until these gaps are remediated.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available |
| Predicted New Indication | Not available |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 — No predictions obtained |
| Taiwan Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available, and the TxGNN model did not return any predicted indications for this compound in the current pipeline run.

Notably, the query log records that both the DrugBank query (ID: 3) and the TFDA package insert query (ID: 4) returned 1 result each, suggesting that source data *does* exist. However, this data was not propagated into the structured fields of the Evidence Pack (e.g., `drugbank_id`, `original_indications`, `original_moa` remain empty or `[Data Gap]`). This is a data pipeline issue that must be resolved before any mechanistic analysis can proceed.

Until the MOA, original indications, and TxGNN prediction outputs are properly populated, no assessment of biological plausibility can be made.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for evaluation under this Evidence Pack.

---

## Literature Evidence

Currently no related literature available under this Evidence Pack.

---

## Taiwan Market Information

RASAGILINE TARTRATE currently holds no marketing authorization in Taiwan. No license records are available.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack is missing the three minimum requirements for evaluation: (1) TxGNN predicted indications, (2) mechanism of action, and (3) safety profile. Without these, neither biological plausibility nor risk can be assessed.

**To proceed, the following is needed:**

- **[Blocking — DG001]** Parse the TFDA package insert PDF (query confirmed 1 result exists) to extract: approved indications, key warnings, and contraindications
- **[High — DG002]** Retrieve mechanism of action and DrugBank ID from the DrugBank record (query confirmed 1 result exists) and populate `drugbank_id`, `original_moa`, and `original_indications` fields
- **[Required]** Re-run the TxGNN prediction pipeline to populate `predicted_indications` — current output is empty, which may indicate a compound name matching issue (consider querying under "Rasagiline" without the salt suffix "tartrate")
- **[Recommended]** Confirm compound identity: check whether RASAGILINE TARTRATE and Rasagiline mesylate (the more commonly marketed salt form) are the same candidate in this context, to avoid missing existing evidence
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

